Reciprocal Space clients, EG 427 and Step Pharma, both headquartered in France, have obtained FDA Investigational New Drug (IND) clearance to initiate Phase 1 clinical trials for their respective investigational therapies. Step Pharma is advancing its CTPS1 inhibitor, dencatistat (STP 938), into clinical trials aimed at treating solid tumors. This inhibitor represents a promising new approach in oncology, targeting a specific enzyme involved in nucleotide biosynthesis, which is essential for the proliferation of cancer cells.

Concurrently, EG 427 has received approval to commence trials for their innovative gene therapy, EG110. This therapy utilizes a herpes simplex virus (HSV) vector to deliver therapeutic genes directly to cells. EG110 is designed to address neurogenic detrusor overactivity (NDO), a form of bladder dysfunction resulting from spinal cord injury. This condition significantly impacts the quality of life for affected individuals, and EG 427's novel approach aims to restore normal bladder function by targeting the underlying neurological causes.

The FDA's clearance for these trials marks a significant milestone for both companies, enabling them to transition from preclinical studies to human trials. This progress underscores the potential of their therapies to address unmet medical needs in oncology and neurogenic bladder disorders, reflecting their commitment to advancing innovative treatments in these challenging fields.